


The Applicants traverse the restriction requirement, but in order to comply with 37 C.F.R. § 1.143, the Applicants elect **Group III (Claims 5, 63, 103-114, 117, 118, 140, and 141)** drawn to products of structure (III) shown in paragraph [0014] on page 6 of the specification, paragraph [0068] on page 26 of the specification, and in claim 5.


Furthermore, to comply with the election of a single species requirement, the Applicants elect, with traverse, **6,7-bis(3-hydroxyphenyl)-pteridine-2,4-diamine** (compound I below):



I

Accordingly, compound I corresponds to the structure (III) of claim 5, wherein the definitions of the substitutions are as follows:

- (a) both Z_2 and Z_4 are C;
- (b) each of Z_1 , Z_3 , Z_5 , and Z_6 is N;
- (c) X is NH_2 , where the substituents X are attached in positions 2 and 4;
- (d) $m = n = 2$; and
- (e) Y is 3-hydroxyphenyl (moiety II below), where the substituents Y are attached in positions 6 and 7.



II

The elected compound I is shown on page 28 (paragraph [0070], right hand compound) and in the table on page 31 (paragraph [0072]), compound III-22, where R = H.

The election of species reads on claims 5, 63, 103, 117, and 118.

The traversal is being made on the following grounds. The Examiner provided the statement that the each group listed in the restriction requirement is patentably distinct over any other group.

However, MPEP § 808 makes it clear that it is not enough for the Examiner to state the reasons why each invention as claimed is independent or distinct. In addition, the Examiner needs to state the reasons why there would be a serious burden on the Examiner if the restriction is not required. It is submitted that the Examiner has not met all the requirements of MPEP § 808, as the Office Action does not provide explanation why, but for the restriction, there would be a serious burden on the Examiner.

Indeed, it is respectfully submitted, that the restriction is unnecessary in this case, as examining all the claims will not impose an undue burden on the Examiner. The number of claims to be examined is not excessively large, and the methods that are claimed are sufficiently related, as are the compounds that are claimed.

In view of the foregoing, reconsideration and withdrawal of the restriction and the election of species requirements are respectfully requested. Should any questions remain

In Re Application Of:
Wrasidlo et al.
Application No. 10/679,209
Filed: October 2, 2003
Page 4

PATENT
Attorney Docket No. TARG1110-3

in view of this communication, the Examiner is encouraged to call the undersigned so that a prompt disposition of this application can be achieved.

No fee is deemed due in connection with this response. However, if any fee is due, the Commissioner is hereby authorized to charge the amount of this fee, or credit any overpayments, to Deposit Account No. 07-1896 referencing the above-identified docket number.

Respectfully submitted,

Date: March 7, 2006



Lisa A. Haile, J.D., Ph.D.
Registration No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

DLA PIPER RUDNICK GRAY CARY US LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133
USPTO Customer No. 28213